Patients were randomized ( 2:1 ratio ) to receive pemetrexed 500 mg/m ( 2 ) intravenously once every 3 weeks plus either oral pazopanib 800 mg daily or cisplatin 75 mg/m ( 2 ) intravenously once every 3 weeks up to six cycles .